"Boron Compounds" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Inorganic or organic compounds that contain boron as an integral part of the molecule.
| Descriptor ID |
D001896
|
| MeSH Number(s) |
D01.132 D02.203
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Boron Compounds".
Below are MeSH descriptors whose meaning is more specific than "Boron Compounds".
This graph shows the total number of publications written about "Boron Compounds" by people in this website by year, and whether "Boron Compounds" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 |
| 1998 | 2 | 0 | 2 |
| 1999 | 0 | 1 | 1 |
| 2004 | 0 | 1 | 1 |
| 2006 | 1 | 0 | 1 |
| 2008 | 0 | 1 | 1 |
| 2010 | 0 | 2 | 2 |
| 2011 | 0 | 1 | 1 |
| 2015 | 0 | 1 | 1 |
| 2016 | 1 | 3 | 4 |
| 2017 | 1 | 2 | 3 |
| 2018 | 0 | 1 | 1 |
| 2019 | 1 | 0 | 1 |
| 2020 | 0 | 2 | 2 |
| 2021 | 0 | 1 | 1 |
| 2022 | 0 | 1 | 1 |
| 2024 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Boron Compounds" by people in Profiles.
-
Active Magnesium Boride/Alginate Hydrogels Rejuvenate Senescent Cells. ACS Nano. 2024 08 27; 18(34):23566-23578.
-
A phase 1-2 trial of DA-EPOCH-R plus ixazomib for MYC-aberrant lymphoid malignancies: the DACIPHOR regimen. Blood Adv. 2024 04 09; 8(7):1612-1620.
-
Reactive metal boride nanoparticles trap lipopolysaccharide and peptidoglycan for bacteria-infected wound healing. Nat Commun. 2022 11 29; 13(1):7353.
-
A phase 2, open-label, multicenter study of ixazomib plus lenalidomide and dexamethasone in adult Japanese patients with relapsed and/or refractory multiple myeloma. Int J Clin Oncol. 2022 Jan; 27(1):224-233.
-
Ixazomib, dexamethasone, and rituximab in treatment-naive patients with Waldenstr?m macroglobulinemia: long-term follow-up. Blood Adv. 2020 08 25; 4(16):3952-3959.
-
Ixazomib for Chronic Graft-versus-Host Disease Prophylaxis following Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2020 10; 26(10):1876-1885.
-
A Mild, DNA-Compatible Nitro Reduction Using B2(OH)4. Org Lett. 2019 04 05; 21(7):2194-2199.
-
Prospective Clinical Trial of Ixazomib, Dexamethasone, and Rituximab as Primary Therapy in Waldenstr?m Macroglobulinemia. Clin Cancer Res. 2018 07 15; 24(14):3247-3252.
-
Phosphodiesterase 4 inhibitors. J Am Acad Dermatol. 2018 03; 78(3 Suppl 1):S43-S52.
-
A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis. Blood. 2017 08 03; 130(5):597-605.